Dimitry S.A. Nuyten, M.D., Ph.D., has been appointed chief medical officer, Aduro Biotech, Inc., a clinical stage biopharma company developing therapies in the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways. Dr. Nuyten joins the company from Pfizer where he most recently served as vice president and Immuno-Oncology Clinical Development Leader, overseeing the clinical strategy for BAVENCIO (avelumab), a human anti-programmed death ligand-1 (PD-L1) a...